Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Open access
Negrao, Marcelo V, Skoulidis, Ferdinandos, Montesion, Meagan, Schulze, Katja, Bara, Ilze, Shen, Vincent, Xu, Hao, Hu, Sylvia, Sui, Dawen, Elamin, Yasir Y, Le, Xiuning, Goldberg, Michael E, Murugesan, Karthikeyan, Wu, Chang-Jiun, Zhang, Jianhua, Barreto, David S, Robichaux, Jacqulyne P, Reuben, Alexandre, Cascone, Tina, Gay, Carl M, Mitchell, Kyle G, Hong, Lingzhi, Rinsurongkawong, Waree, Roth, Jack A, Swisher, Stephen G, Lee, Jack, Tsao, Anne, Papadimitrakopoulou, Vassiliki, Gibbons, Don L, Glisson, Bonnie S, Singal, Gaurav, Miller, Vincent A, Alexander, Brian, Frampton, Garrett, Albacker, Lee A, Shames, David, Zhang, Jianjun, Heymach, John V·2021·Journal for ImmunoTherapy of Cancer

Abstract

Background: Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in these markers and clinical outcome. Methods: Three cohorts of NSCLC patients with oncogene alterations (n=4189 total) were analyzed. Two clinical cohorts of advanced NSCLC patients treated with ICB monotherapy [MD Anderson (MDACC; n=172) and Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB; n=894 patients)] were analyzed for clinical outcome. The FMI biomarker cohort (n=4017) was used to assess the association of oncogene alterations with TMB and PD-L1 expression. Results: High PD-L1 expression (PD-L1 ≥50%) rate was 19%–20% in classic EGFR, EGFR exon 20 and HER2-mutant tumors, and 34%–55% in tumors with ALK, BRAF V600E, ROS1, RET, or MET alterations. Compared with KRAS-mutant tumors, BRAF non-V600E group had higher TMB (9.6 vs KRAS 7.8 mutations/Mb, p=0.003), while all other oncogene groups had lower TMB (p<0.001). In the two clinical cohorts treated with ICB, molecular groups with EGFR, HER2, ALK, ROS1, RET, or MET alterations had short progression-free survival (PFS; 1.8–3.7 months), while BRAF V600E group was associated with greater clinical benefit from ICB (CGDB cohort: PFS 9.8 months vs KRAS 3.7 months, HR 0.66, p=0.099; MDACC cohort: response rate 62% vs KRAS 24%; PFS 7.4 vs KRAS 2.8 months, HR 0.36, p=0.026). KRAS G12C and non-G12C subgroups had similar clinical benefit from ICB in both cohorts. In a multivariable analysis, BRAF V600E mutation (HR 0.58, p=0.041), PD-L1 expression (HR 0.57, p=0.022), and high TMB (HR 0.66, p<0.001) were associated with longer PFS. Conclusions: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors. Meanwhile EGFR and HER2 mutations and ALK, ROS1, RET, and MET fusions define NSCLC subsets with minimal benefit from ICB despite high PD-L1 expression in NSCLC harboring oncogene fusions. These findings indicate a TMB/PD-L1-independent impact on sensitivity to ICB for certain oncogene alterations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2021-002891

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 294

Metadata

Authors
Negrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bara, I., Shen, V., Xu, H., Hu, S., Sui, D., Elamin, Y. Y., Le, X., Goldberg, M. E., Murugesan, K., Wu, C.-J., Zhang, J., Barreto, D. S., Robichaux, J. P., Reuben, A., Cascone, T., Gay, C. M., Mitchell, K. G., Hong, L., Rinsurongkawong, W., Roth, J. A., Swisher, S. G., Lee, J., Tsao, A., Papadimitrakopoulou, V., Gibbons, D. L., Glisson, B. S., Singal, G., Miller, V. A., Alexander, B., Frampton, G., Albacker, L. A., Shames, D., Zhang, J., & Heymach, J. V.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-08
Volume
9
Issue
8
Pages
e002891
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3192028440
Cited by
294
References
45
FWCI
14.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. https://app.cochat.ai/papers/10.1136/jitc-2021-002891
The paper
Negrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bara, I., Shen, V., Xu, H., Hu, S., Sui, D., Elamin, Y. Y., Le, X., Goldberg, M. E., Murugesan, K., Wu, C.-J., Zhang, J., Barreto, D. S., Robichaux, J. P., Reuben, A., Cascone, T., . . . Heymach, J. V. (2021). Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.